A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 117



Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu-Chou Su, Jhanelle E Gray, Siow-Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S Ramalingam. N Engl J Med 2018
Times Cited: 1692




List of shared articles



Times cited

Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC.
Julia Roeper, Sylke Kurz, Christian Grohé, Frank Griesinger. Future Oncol 2021
2

EGFR-mutant NSCLC: emerging novel drugs.
Lingyun Ye, Xiaoxia Chen, Fei Zhou. Curr Opin Oncol 2021
1

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.
Julia Lai-Kwon, Crescens Tiu, Abhijit Pal, Sachin Khurana, Anna Minchom. Crit Rev Oncol Hematol 2021
3

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
2

GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.
Xiyin Li, Hairui Wang, Xing Yang, Xiaoqi Wang, Lina Zhao, Li Zou, Qin Yang, Zongliu Hou, Jing Tan, Honglei Zhang,[...]. Cancer Lett 2021
0

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.
Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R Joseph, Fiona Simpson. Cells 2021
2

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
Ryoji Kato, Hidetoshi Hayashi, Kazuko Sakai, Shinichiro Suzuki, Koji Haratani, Takayuki Takahama, Junko Tanizaki, Yoshikane Nonagase, Kaoru Tanaka, Takeshi Yoshida,[...]. Int J Clin Oncol 2021
1


Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer.
Yiming Zhao, Shuyuan Wang, Zhengyu Yang, Yu Dong, Yanan Wang, Lele Zhang, Hai Hu, Baohui Han. Front Oncol 2021
0

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.
Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux, Michèle Beau-Faller. Cancers (Basel) 2021
0

Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer.
V H F Lee, T S K Mok, Y Goto, V C C Hsue, L Yang, Y Jiang, D K C Leung, K S Lau, P Y Tse. Clin Oncol (R Coll Radiol) 2020
1

Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Carlo Genova, Giovanni Rossi, Marco Tagliamento, Erika Rijavec, Federica Biello, Luigi Cerbone, Lodovica Zullo, Francesco Grossi. Expert Rev Respir Med 2020
8


ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu,[...]. Clin Cancer Res 2020
17

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
G R Oxnard, J C-H Yang, H Yu, S-W Kim, H Saka, L Horn, K Goto, Y Ohe, H Mann, K S Thress,[...]. Ann Oncol 2020
86





Molecular therapeutic targets in non-small cell lung cancer.
Kamya Sankar, Shirish M Gadgeel, Angel Qin. Expert Rev Anticancer Ther 2020
8